All In Biotech

Drug Trial Radar · NCT06982729

Study of YK012 in Primary Membranous Nephropathy

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YK012 in the Treatment of Primary Membranous Nephropathy

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 8, 2025

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).

Conditions

  • Primary Membranous Nephropathy

Interventions

  • YK012Drug

    YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ia: Dose-limiting Toxicity(DLT)Time frame: up to 28 days after the first dose
  2. Ia: Adverse Event (AE)Time frame: From the first induction to the end of the trial at 53 weeks
  3. Ia: Severe Adverse EventTime frame: From the first induction to the end of the trial at 53 weeks
  4. Ib: Proportion of participants achieving overall responseTime frame: From enrollment to the end of the trial at 76 weeks (if applicable)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.